Aripiprazole/sertraline

From Wikipedia, the free encyclopedia
Aripiprazole/sertraline
Combination of
AripiprazoleAtypical antipsychotic
SertralineSelective serotonin reuptake inhibitor
Clinical data
Other namesASC-01
Routes of
administration		By mouth
Legal status
Legal status
  • US: Investigational New Drug

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1]

See also[]

References[]

  1. ^ a b c "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""